Related Experiment Videos

Intra-abdominal sepsis: a medical-surgical dilemma

A W Hackford1

  • 1New England Medical Center Hospital, Boston, Massachusetts.

Clinical Therapeutics
|January 1, 1990
PubMed

Insights

Intra-abdominal infections involve both aerobic and anaerobic bacteria, requiring broad-spectrum antibiotics. Despite advances, sepsis from these infections remains a leading cause of intensive care unit mortality, necessitating new treatment strategies.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Critical Care Medicine

Background:

  • Intra-abdominal infections (IAIs) have a complex pathophysiology involving aerobic and anaerobic microorganisms.
  • Understanding of IAIs evolved over a century, with key insights into peritonitis and abscess formation by the 1970s.
  • Improved culture techniques reveal the polymicrobial nature of IAIs, with an average of 3.9 isolates per patient.

Purpose of the Study:

  • To review the pathophysiology and treatment of intra-abdominal infections.
  • To highlight the challenges posed by polymicrobial flora in antibiotic selection.
  • To discuss mortality factors and future directions in managing sepsis secondary to IAIs.

Main Methods:

  • Literature review of the pathophysiology of intra-abdominal infections over the past 100 years.
  • Analysis of historical and recent findings on microbial components (aerobic and anaerobic) in IAIs.
  • Discussion of current antibiotic strategies and their limitations.

Main Results:

  • IAIs are polymicrobial, necessitating antibiotic regimens active against both aerobic and anaerobic bacteria.
  • Current antibiotic approaches often involve combinations, though single-agent regimens are emerging.
  • Despite advances, IAIs leading to sepsis remain a primary cause of death in intensive care units.

Conclusions:

  • Effective management of IAIs requires addressing both aerobic and anaerobic components.
  • Mortality in IAIs is linked to recurrent abscesses, positive blood cultures, and organ failure.
  • Future reductions in mortality will likely depend on modulating sepsis-related metabolic and immune pathways, rather than solely on broader antibiotics or surgery.

Related Concept Videos